Global Leading Market Research Publisher QYResearch announces the release of its latest report “Low Borosilicate Pharmaceutical Glass Tube – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Low Borosilicate Pharmaceutical Glass Tube market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical manufacturers, glass delamination and extractable/leachable contamination threaten drug stability and patient safety. Standard soda-lime glass (Type III) has poor chemical resistance, leading to glass flaking in injectable drugs. Low borosilicate pharmaceutical glass tubes (Type I) directly solve these integrity challenges. With excellent hydrolytic resistance (Class I), low coefficient of thermal expansion, and minimal extractables, Type I glass tubes are converted into vials, cartridges, and syringes for biologics, vaccines, and sensitive injectable drugs.
The global market for Low Borosilicate Pharmaceutical Glass Tube was estimated to be worth US$ 2,800 million in 2025 and is projected to reach US$ 4,200 million, growing at a CAGR of 6.0% from 2026 to 2032. Key growth drivers include injectable drug expansion, biologics growth, and conversion from Type III to Type I glass.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/5985881/low-borosilicate-pharmaceutical-glass-tube
1. Market Dynamics: Updated 2026 Data and Growth Catalysts
Based on recent Q1 2026 pharmaceutical packaging data, three primary catalysts are reshaping demand for low borosilicate pharmaceutical glass tubes:
- Injectable Drug Growth: Global injectable drug market ($500B+) growing 8-10% annually. Prefilled syringes and vials require Type I glass.
- Biologics Expansion: Biologics (mAbs, vaccines, gene therapies) are sensitive to glass interactions. Type I glass offers superior chemical resistance.
- Type III to Type I Conversion: Regulatory pressure (FDA, EMA) encourages conversion to prevent delamination. Type I adoption increasing 5-7% annually.
The market is projected to reach US$ 4,200 million by 2032, with control bottle (tubular glass) maintaining larger share (70%) for vials and syringes, while molded bottles (30%) serve infusion and oral dosage.
2. Industry Stratification: Manufacturing Process as a Product Differentiator
Control Bottle (Tubular Glass)
- Primary characteristics: Glass tube converted into vials, cartridges, syringes. Higher precision, thinner walls, lighter weight. Preferred for injectable drugs. Largest segment (70% market share). Cost: $0.10-1.00 per converted unit.
- Typical user case: Prefilled syringe manufacturer uses low borosilicate tube — converts to 1mL syringe barrel for biologic drug.
Molded Bottles
- Primary characteristics: Glass formed in mold. Thicker walls, heavier weight. Used for large-volume infusion bottles (50-1,000mL) and oral dosage. 30% market share. Cost: $0.20-2.00 per unit.
- Typical user case: Infusion bottle manufacturer uses molded low borosilicate — 250mL Type I glass for IV solutions.
3. Competitive Landscape and Recent Developments (2025-2026)
Key Players: Corning (US, Valor Glass), SCHOTT Pharma (Germany, market leader), Antylia, Shangdong Pharmaceutical Glass (China), DWK Life Sciences (US), ZHENG CHUAN (China), Borosil (India), GSC International, FOUR STARS GLASS (China), LINUO (China), NIPRO (Japan), SHENYU (China), Sumspring (China), JIYUAN ZHENGYU (China), BEIYUAN GLASS (China), Jin Yuelai (China)
Recent Developments:
- Corning expanded Valor Glass (November 2025) — alkali-free, low extractables, $2,500/ton.
- SCHOTT launched FIOLAX Pro (December 2025) — Type I, enhanced chemical resistance, $2,200/ton.
- Shangdong Pharmaceutical increased capacity (January 2026) — 100,000 tons/year, China.
- Borosil expanded India production (February 2026) — 50,000 tons/year.
Segment by Type:
- Control Bottle (70% market share) – Vials, cartridges, syringes.
- Molded Bottles (30% share) – Infusion, oral dosage.
Segment by Application:
- Injection Bottle (largest segment, 40% market share) – Injectable drugs.
- Infusion Bottle (25% share) – IV solutions.
- Oral Dosage Bottle (20% share) – Liquid oral medications.
- Other (15%) – Diagnostic reagents, vaccines.
4. Original Insight: The Overlooked Challenge of Hydrolytic Resistance and Delamination Prevention
Based on analysis of 100+ glass specifications (September 2025 – February 2026), critical quality factors are hydrolytic resistance and delamination risk:
| Glass Type | Hydrolytic Resistance (ISO 719) | Delamination Risk | Extractable Levels | Cost Premium | Best for |
|---|---|---|---|---|---|
| Type III (soda-lime) | Class III (low) | High | High | Baseline | Oral drugs |
| Low borosilicate (Type I) | Class I (highest) | Low | Low | +30-50% | Injectable, biologics |
| Alkali-free (Valor) | Class I (highest) | Very low | Very low | +50-80% | High-sensitivity biologics |
独家观察 (Original Insight): Delamination (glass flaking) is a critical safety issue for injectable drugs. Low borosilicate Type I glass has significantly lower delamination risk than Type III. For high-sensitivity biologics, alkali-free glass (Corning Valor) offers even lower extractable levels. Our analysis recommends: (a) oral drugs: Type III, (b) injectable: low borosilicate Type I, (c) biologics: alkali-free glass. Chinese manufacturers offer lower-cost Type I glass (10-20% discount to SCHOTT/Corning).
5. Low Borosilicate vs. Other Glass Types (2026 Benchmark)
| Parameter | Low Borosilicate (Type I) | Soda-Lime (Type III) | Alkali-Free |
|---|---|---|---|
| Hydrolytic resistance | Class I (highest) | Class III (low) | Class I |
| Delamination risk | Low | High | Very low |
| Chemical durability | Excellent | Poor | Excellent |
| Cost (vs Type III) | +30-50% | Baseline | +50-80% |
| Best for | Injectable, biologics | Oral drugs | High-sensitivity biologics |
6. Regional Market Dynamics
- Asia-Pacific (45% market share, fastest-growing): China (Shangdong, ZHENG CHUAN, LINUO, SHENYU, Sumspring, JIYUAN, BEIYUAN, Jin Yuelai). India (Borosil). Japan (NIPRO).
- North America (30% share): US (Corning, SCHOTT, Antylia, DWK).
- Europe (25% share): Germany (SCHOTT).
7. Future Outlook and Strategic Recommendations (2026-2032)
By 2028 expected:
- Alkali-free glass adoption for biologics
- High-volume Type I conversion in China and India
- Glass tube recycling programs
- Cost reduction through Chinese manufacturing scale
For pharmaceutical manufacturers, low borosilicate pharmaceutical glass tubes provide essential chemical resistance for injectable drugs. Control bottle (tubular) glass (70% market) dominates vials and syringes. Type I glass is the gold standard for biologics. Key selection factors: (a) hydrolytic resistance (Class I), (b) delamination risk (low), (c) extractable profile, (d) cost ($2,000-2,500/ton). As injectable drug demand grows, the market will grow at 6% CAGR through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
